

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM486365

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
KAYNE ANDERSON MEZZANINE PARTNERS (QP), LP		08/14/2018	Limited Partnership:
RECEIVING PARTY DATA			
Name:	NEPHRON PHARMACEUTICALS CORPORATION		
Street Address:	4500 12TH STREET EXTENSION		
City:	WEST COLUMBIA		
State/Country:	SOUTH CAROLINA		
Postal Code:	29172		
Entity Type:	Corporation: FLORIDA		
PROPERTY NUMBERS Total: 9			
Property Type	Number	Word Mark	
Registration Number:	4235335	ASTHMANEFRIN	
Registration Number:	4263237	NEPHRON PHARMACEUTICALS CORPORATION	
Serial Number:	85518101	VAPONEFRIN	
Serial Number:	85729590	EZ BREATHE ATOMIZER	
Registration Number:	1707750	S2	
Serial Number:	85725993	S2	
Serial Number:	86236644	X-AIR	
Serial Number:	86172055	LEVAL-X	
Serial Number:	86172014	ALBUTER-X	
CORRESPONDENCE DATA			
Fax Number:	8032538277		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	803-540-2185		
Email:	shutto@nexsenpruet.com		
Correspondent Name:	Todd A. Serbin, Nexsen Pruet, LLC		
Address Line 1:	PO Box 2426		
Address Line 4:	Columbia, SOUTH CAROLINA 29202-2426		

CH \$240.00 4235335

ATTORNEY DOCKET NUMBER:	54232-12
NAME OF SUBMITTER:	TODD A. SERBIN
SIGNATURE:	/Todd A. Serbin/
DATE SIGNED:	08/16/2018
Total Attachments: 3 source=Nephron - Trademark Release (Executed)#page1.tif source=Nephron - Trademark Release (Executed)#page2.tif source=Nephron - Trademark Release (Executed)#page3.tif	

TRADEMARK RELEASE AND REASSIGNMENT

THIS TRADEMARK RELEASE AND REASSIGNMENT is made as of August 14, 2018, by Kayne Anderson Mezzanine Partners (QP), LP, as collateral agent (“Collateral Agent”). Capitalized terms used but not defined herein shall have the same meanings assigned to such terms in the Security Agreement (as defined below).

WITNESSETH:

WHEREAS, Nephron Pharmaceuticals Corporation, a Florida corporation (“Grantor”) entered into an Assignment For Security – Trademarks, dated as of June 30, 2016 (the “Security Agreement”), pursuant to which Grantor granted a security interest to Collateral Agent for the benefit of the Purchasers, in the Collateral as security for certain obligations owing by Grantor to the Purchasers including certain trademarks (the “Trademarks”) set forth on Schedule A hereto; and

WHEREAS, the Security Agreement was recorded by the United States Patent and Trademark Office on July 1, 2016 at Reel 5827, Frame 0312; and

WHEREAS, Grantor has requested that Collateral Agent release its security interest in the Trademarks and Collateral and reassign the same to Grantor.

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged:

1. Collateral Agent hereby releases its security interest in all of Grantor’s right, title and interest in and to the Collateral, including the Trademarks set forth on Schedule A.

2. Collateral Agent hereby reassigns, grants and conveys to Grantor, without any representation, recourse, warranty or undertaking by Collateral Agent, all of Collateral Agent’s right, title and interest in and to the Collateral and the Trademarks.

- Remainder of Page Intentionally Left Blank; Signature Page Follows -

IN WITNESS WHEREOF, Collateral Agent has caused this Trademark Release and Reassignment to be executed as of the day and year first above written.

**KAYNE ANDERSON MEZZANINE
PARTNERS (QP), LP, as Collateral Agent**

By: Kayne Anderson Mezzanine Advisors,
LLC, as General Partner

By: 
Name: Terrence Quinn
Title: Vice Chairman

Trademark Release and Reassignment

**TRADEMARK
REEL: 006431 FRAME: 0028**

SCHEDULE A

TRADEMARKS

Name of Owner		Ownership Percentage	Jurisdiction(s)	Registration Office or Common Law	Serial Or Registration No.
Nephron Pharmaceuticals Corporation	Asthmanefrin	100%	United States	USPTO	Reg. No. 4,235,335
Nephron Pharmaceuticals Corporation	Nephron Pharmaceuticals Corporation	100%	United States	USPTO	Reg. No. 4,263,237
Nephron Pharmaceuticals Corporation	Nephron Pharmaceutical Corporation	100%	EU	OHIM	Reg. No. 1097027
Nephron Pharmaceuticals Corporation	Nephron Pharmaceuticals Corporation	100%	United States, EU	Common Law	
Nephron Pharmaceuticals Corporation	Vaponefrin	100%	United States	USPTO	Ser. No. 85/518101 (intent-to-use)
Nephron Pharmaceuticals Corporation	Ez Breathe Atomizer	100%	United States	USPTO	Ser. No. 85/729590
Nephron Pharmaceuticals Corporation	S2	100%	United States	USPTO	Reg. No. 1,707,750
Nephron Pharmaceutical Corporation	S2	100%	United States	USPTO	Ser. No. 85/725993
Nephron Pharmaceuticals Corporation	X-Air	100%	United States	USPTO	Ser. No. 86236644 (intent-to-use)
Nephron Pharmaceuticals Corporation	Leval-X	100%	United States	USPTO	Ser. No. 86172055 (intent-to-use)
Nephron Pharmaceuticals Corporation	Albuter-X	100%	United States	USPTO	Ser. No. 86172014 (intent-to-use)

TRADEMARK